Table 1.
Selected results of clinical studies on CAR-T-cells
| Study | Disease | Target | CAR dose (× 106/kg) | Patient No. | Efficacy | Survival/duration | CRS |
|---|---|---|---|---|---|---|---|
| Maude et al. 2014 | R/R B-ALL | CD19 | 0.76–20.6 | 30 | CR 90% | 6 m EFS 67%, 6 m OS 78% | 27% (severe) |
| Lee et al. 2014 | ALL/NHL | CD19 | 0.03–3.6 | 21 | CR/CRi 66.7% | OS 51.6% at 9.7 months | 76% (total) |
| Neelapu et al. 2017 | NHL | CD19 | 2 | 101 | CR 54% | OS 52% at 18 months | 13% (≥ grade 3) |
| Fry et al. 2018 | R/R B-ALL | CD22 | 0.3–3 | 21 | CR 57% | Median duration: 6 months | 76% (total) |
| Pan et al. 2019 | R/R B-ALL | CD22 | 0.02–3.47 | 34 | CR/CRi 70.5% | 1-year LFS 71.6% | 91% (total) |
| Raje et al. 2019 | MM | BCMA | 50–800 × 106 (total) | 33 | CR 45% | Median PFS: 11.8 months | 76% (total) |
| Cohen et al. 2019 | MM | BCMA | 10–500 × 106 (total) | 25 | OR 20%–64% | Median PFS: 2.2–4.2 months | 88% (total) |
| Wang et al. 2017 | HL | CD30 | 11–21 | 18 | OR 39% | Median PFS: 6 months | 11% (≥ grade 3) |
| Ramos et al. 2017 | HL/ALCL | CD30 | 20–200 × 106/m2 | 9 | CR 33% | CR duration: 9–36 months | NA |
| Wang et al. 2020EHA | T-ALL | CD7 | 6–15 | 5 | CR 80% | NA | 100% |
CR, complete response; CRS, cytokine release syndrome; EFS, event-free survival; OS, overall survival; OR, objective response; PFS, progression free survival.